Children's Oncology Group's 2013 blueprint for research: renal tumors
Quality Assurance Review Center
Health Services Administration | Neoplasms | Oncology | Pediatrics | Radiology
Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.
DOI of Published Version
Pediatr Blood Cancer. 2013 Jun;60(6):994-1000. doi: 10.1002/pbc.24419. Epub 2012 Dec 19. Link to article on publisher's site
Pediatric blood and cancer
Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, Gratias EJ, Dix DB, Ehrlich PF, Khanna G, Malogolowkin MH, Anderson JR, Naranjo A, Perlman EJ. (2013). Children's Oncology Group's 2013 blueprint for research: renal tumors. IROC Rhode Island (QARC) Publications. https://doi.org/10.1002/pbc.24419. Retrieved from https://escholarship.umassmed.edu/qarc/25